Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Our program fits into real life
As your body becomes more insulin-sensitive on GLP-1 therapy, blood sugar may dip more rapidly between meals if you're eating smaller portions
To keep patients safe and outcomes strong, consider the following clinical best practices: Start low, go slow on dosing Monitor for GI symptoms, especially early on Revisit mental health and vision concerns routinely Avoid use in patients with thyroid cancer history Stay alert for signs of pancreatitis or gallbladder issues Smart oversight matters
On November 2023, the United States Food and Drug Administration (FDA) has approved Eli Lilly and Company s Zepbound (tirzepatide) injection, the first and only obesity medication to activate both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
Coverage is determined after prior authorization is completed and based on your individual insurance plan
Individual cases have been documented
US$ 26.36
US$ 26.66
US$ 21.95
